As the cell and gene therapy (CGT) industry rapidly expands, maintaining product safety and quality is more critical than ever. One of the most pressing concerns is the threat of adventitious agents—unintended microbial contaminants that can derail development, delay regulatory approval, and pose serious risks to patients.
This insightful article delves into the evolving landscape of contamination detection in CGTs, highlighting cutting-edge technologies and strategies that enhance the identification and control of potential contaminants. By exploring these innovations, stakeholders can better navigate the complexities of CGT production, ensuring both the safety of therapies and the trust of patients.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
By submitting this form, you consent to Cell & Gene Therapy Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.